Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Hi-Tech Pharmacal/Health Care Products' Nasal-Ease product infringes Quigley's Cold-Eeze and Kids-Eeze marks, Doylestown, Penn.-based Quigley alleges in a lawsuit filed March 24 in Philadelphia federal court. Hi-Tech's use of the Nasal-Ease name is "likely to cause confusion, or to cause mistake or to deceive," the suit maintains. In addition to trademark infringement, the suit alleges false advertising under the Lanham Act, unfair competition and false designation of origin and common law unfair competition. Quigley takes issue with Hi-Tech's reference in ads to studies examining the effect of zinc on the common cold, including the Cleveland Clinic study of 1996 and the 1993 Dartmouth study, both of which support the use of zinc to reduce the duration of the common cold. Health Care Products says the suit is without merit. Cold-Eeze has been presented with a Edison gold award for best new product by the American Marketing Association. The award was selected by a panel of 3,500 senior marketing and advertising execs...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts